Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00383
2013-12-17
Prospective
Nil
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Nil
Not Applicable
Ms. Jennifer Tsoi
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon
3943 5869
jennifertsoi@cuhk.edu.hk
The Chinese University of Hong Kong
Hong Kong
Dr. Yam Cheuk Sing Jason
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon
39435892
yamcheuksing@gmail.com
The Chinese University of Hong Kong
Hong Kong
Evaluation of different concentration of low dose topical atropine in retarding myopia progression
Evaluation of different concentration of low dose topical atropine in retarding myopia progression
不同濃度阿托品眼藥水在近視加深控制之研究
Low dose atropine for myopia progression study
Hong Kong
Yes
2013-11-19
Kowloon Central Cluster REC / Kowloon East Cluster REC
KC/KE-13-0182/FR-2
Myopia
Drug
Atropine
Eyedrop
Group 1 will use 0.1% atropine eyedrop daily, Group 2 will use 0.05% atropine eyedrop daily, Group 3 will use 0.025% atropine eyedrop daily. Group 4 will use 0.01% atropine eyedrop once daily. Group 5 will receive the placebo eyedrop.
2 years
Once Daily
Normal saline(Placebo)
Eyedrop
0.9%
2 years
Once Daily
Age 4 to 12
Myopia : SE -1 to -10 D
Astigmatism: < 2.5 D
Anisometropia : < 2.0 D
History of myopia progression > 0.5 D for Both eyes in one year
Informed parental consent
Ophthalmic diseases other than refractive errors
Previous use of treatment of atropine
Allergy or intolerance to atropine
Inability to attend regular follow up assessment
4
12
Both Male and Female
Interventional
Randomized
Subjects will be assigned to 5 arms
Placebo
Double-blind
Parallel
4
2014-01-02
520
Recruiting
-Change in spherical equivalent refraction (cycloplegic refraction)
-Change in axial length
-Safety variable: Best corrected visual acuity, pupil size, intraocular pressure
2021-07-07
ChiCTR-TRC-13004032
2013-12-24
|
|
|
|
|
---|---|---|---|---|
No documents yet. |